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Summan Granulocyte colony stimulating factor (G-CSF) was given to 17 patients with advanced breast and
ovarian cancer in order to increase the intensity and effectiveness of chemotherapy. Treatment with
doxorubicin. at doses of 75mgm-2 (n=4 patients). lOOmgm-2 (n=5). 125mgm-2 (n=6) and 15Omgm-2
(n=2). was followed by infusion of G-CSF for 11 days. G-CSF administration resulted in a return of the
absolute neutrophil count to normal or above normal levels within 12-14 days at all dose levels of
doxorubicin used and allowed the administration of up to three cycles of high dose chemotherapy at 14 day
intervals. An absolute neutrophil count >2.5 x 1091 -1 was not reached until day 19-21 after 75 mg m -' of
doxorubicin given without G-CSF. At doses of doxorubicin of 125 mgm -2 and 150mg m-2 all tumours
regressed rapidly. although there was marked epithelial toxicity. The overall response rate in patients with
advanced breast cancer was 80% with a median time to progression of 6 months. Two months after
doxorubicin-G-CSF therapy there was a pronounced improvement of symptoms compared with before
treatment. Thus the effectiveness of chemotherapy may be enhanced and treatment duration shortened by the
use of G-CSF infusions. Further studies of this promising approach are warranted.
The gene for G-CSF has recently been isolated and
expressed in E. coli (Souza et al.. 1986). Recombinant
human G-CSF has been shown to promote the growth and
differentiation of myeloid precursors to form functional
neutrophils both in vitro and in vivo (Souza et al., 1986;
Bronchud et al.. 1988). In patients, infusions of
140 ugkg-I dayv- of G-CSF produce a six- to ten-fold
increase in numbers of peripheral blood neutrophils with no
significant toxicity and no appreciable change in
haemoglobin or platelet and lymphocyte counts (Bronchud
et al.. 1987). When given in association with intensive
chemotherapy. G-CSF reduced the period of neutropenia by
a median of 80% with a significant decrease in the number
of severe infections (Bronchud et al., 1987). In view of these
striking effects of G-CSF we wished to investigate whether
its use would allow us to improve response and symptoms
by increasing the dose of doxorubicin and decreasing the
overall duration of treatment in women with advanced
breast and ovarian cancer.
Doxorubicin is commonly regarded as the most active
chemotherapeutic single agent in the treatment of breast
cancer and results in objective remissions in 40-57% of
patients (Hoogstraten, 1975; Steiner et al., 1983). When
given in conventional doses it has not been found to be
clinically useful in advanced ovarian carcinoma recurrent
after chemotherapy (Hubbard et al., 1978), but higher doses
are sometimes effective (Wheeler et al., 1982). The
therapeutic dose-response curve for doxorubicin is known to
be steep in experimental animal systems (Frei & Canellos.
1980), and a dose-response effect has been shown in patients
with a variety of solid tumours (Wheeler et al., 1982; Cortes
et al.. 1978). A high dose-intensity of treatment, defined as
the amount of cytotoxic drug administered per unit time, is
also known to improve response rates in patients with
advanced breast cancer (Jones et al.. 1987; Carmo-Pereira et
al.. 1987). However, when doxorubucin was given at
120 mgm-2 every 3 weeks (Wheeler et al., 1982) or at
135mgm-2 every 4 weeks (Jones et al., 1987) life-threatening
mediastinal irradiation. and a serum bilirubin >25 mmol I-
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several patients died of infectious complications. Here we
show that it is possible to give high doses of doxorubicin
every 2 weeks by using infusions of G-CSF. It has been
suggested that clinical trials in patients with advanced solid
tumours should include an assessment of the quality of life
of patients (Brinkley, 1985). We used the Rotterdam
Symptom Checklist, a self-evaluation questionnaire designed
for use with cancer patients.
Patients and methods
Patients
Twenty-one patients were entered in this study. 19 with
progressive histologically proven metastatic breast cancer
resistant to endocrine therapy and two with ovarian
carcinoma recurrent after chemotherapy. Their median age
was 53 (range 30-67), 15 received G-CSF and doxorubicin
(Adriamycin, Farmitalia) given every 2 weeks for a total of
three cycles. at the following doses: 75mgm-2 (4 patients),
OOmgm-2 (5 patients). 125 mgm-2 (6 patients). Two more
patients received G-CSF and 150mgm- of doxorubicin for
a total of two cycles only. Four patients were treated with
conventional doses of 75mgm-2, without G-CSF, as
controls; it was planned that they should be treated every 2
weeks if the neutrophil count rose to more than 2.5 x 1091
at this time. The treatment plan is shown in Figure 1 and
pre-treatment patient characteristics are summarised in Table
I. None of the 15 patients with metastatic breast cancer
treated with G-CSF had received previous chemotherapy,
but all had received previous radiotherapy (to less than 50%
of their active bone marrow). Eleven of these patients had
more than two sites of disease and all had considerable
tumour burden as assessed both clinically and radiologically
(Table I). The two patients with recurrent ovarian carcinoma
were previously treated with cisplatinum and cyclo-
phosphamide containing regimens. All patients had
measurable and/or evaluable disease and a performance
score of 0-3 on the WHO scale. Exclusion criteria included
any history of congestive heart failure or significant
arrhythmias, previous anthracycline therapy, significant
mediastinal irradiation, and a serum bilirubin >25 rmol 1 1,
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Figwe I Treatment plan. MUGA, multiple-gated acquisition scans to measure left ventriular ejection fraction; ECG,
electrocardiogram; Q of L. quality of life questionnaire. *Both MUGA scans and Q of L were repeated 2 months after completion
of chemotherapy.
Table I Patient characteristics before therapy, dose of doxorubicin, chemotherapy cycles and response
patterns
Prey. therapy
Doxo. dose CT Response
Patient RT CT (mgm-2) cycles Sites of disease to CT
l(B) yes no 75 3 lung, pleura PR
2(B) no no 75 3 skin, nodes, breast, bone PR
3(B) yes no 75 3 lung, liver NR
4(0) yes yes 75 3 pelvis, abdomen, nodes PR
5(B) yes no 100 3 skin, nodes, bone, breast CR*
6(B) yes no 100 2 skin, nodes, bone, liver, lung NR
6R(B) yes no 100 3 bone, liver NR
7(B) yes no 100 3 skin, abdomen, pelvis PR
8(B) yes no 100 3 bone, liver PR
9(B) yes no 125 3 skin, nodes, bone PR
10(0) no yes 125 3 abdomen, pelvis PR
Il(B) yes no 125 3 nodes, pleura, lung, liver, bone PR
12(B) yes no 125 3 nodes, skin, lung CR
15(B) yes no 125 3 nodes, skin, bone, liver CR*
16(B) yes no 125 3 nodes, skin, lung CR
13(B) yes no 150 2 nodes, bone, lung, liver PR
14(B) yes no 150 2 nodes, skin, bone, liver CR*
17(B) yes no 75 3 nodes, liver PR
18(B) no no 75 3 breast, nodes, bone PR
19(B) yes no 75 1 bone, liver NR
20(B) no no 75 3 breast, nodes NR
RT, radiotherapy; CT, chemotherapy; NR, no response; PR, partial response; CR, complete response; B,
breast primary; 0, ovarian primary. Patients 17-20 are controls, receiving no G-CSF. *CR in sites other than
bone.
Informed consent was obtained from all patients; the study
protocol was approved by South Manchester ethical
committee.
Clinical and laboratory monitoring
Before each course of chemotherapy all palpable or
superficial lesions were measured in two perpendicular
diameters and visible lesions photographed. Base line studies
included a chest radiograph, an isotopic bone scan with
radiographs of areas of increased uptake, and haemato-
logical and biochemical screens. Isotopic liver scans were
performed in patients with abnormal liver function tests. All
patients underwent resting multiple-gated acquisition
(MUGA) scans before each course of chemotherapy, after
completion of therapy and 2-4 months later. The ejection
fraction (LVEF) was calculated from the volume change in
the left ventricle using standard methods and the pre-
treatment value was required to be >40% (minimal normal
value at our centre). Electrocardiograms were performed
before starting chemotherapy and when indicated. Patients
were managed as outpatients attending a day ward clinic
three times a week for blood counts for a total of 6 weeks.
Doxorubicin was infused via a central vein catheter in 250ml
saline over 30min in order to minimise peak levels.
Recombinant human G-CSF was supplied by AMGEN
(Thousand Oaks, CA, USA) and was administered as a
continuous infusion as previously described (Bronchud et al.,
1987). The infusion pump (CADD-1 model, Pharmacia) was
programmed to give lI0gkg- I day-1 of G-CSF from day 1
after chemotherapy to day 8 and 5ugkg 1day- I from day 8
to day 11 ofeach cycle. This was followed by 2 days without
growth factor to allow normalisation of peripheral blood
counts.
Non-cardiac toxicities were documented according to
WHO scores and, if visible, photographed. Patients were
given prophylactic antiseptic mouthwashes and warned
about possible mucositis. Patients were asked to complete
the Rotterdam Symptom Checklist (de Haes et al., 1983), a
self-rating scale designed to measure psychological status
(depression and anxiety), physical complaints (symptoms of
disease and treatment toxicity) and functional status (ranging
from personal care to going out shopping). Questionnaires
were administered by a specialist nurse at study entry, on
completion of chemotherapy and 2 months later. The
psychological subscale of the questionnaire had been
validated in women with advanced breast cancer, attending
the same clinic, and an appropriate cut-off score established.
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Scores > 10 suggest clinically important levels of depression
and anxiety (Hopwood et al., in preparation). Functional
status was quantified as per cent of the maximum disability
score. Pain and shortness of breath were analysed
individually, using a scoring of 0 (not at all), 1, 2 and 3
(severe).
All patients were evaluated for response according to
Hayward et al. (1977). Time to progression was from the
beginning of chemotherapy until either new lesions appeared
or any one existing lesion increased by 25% or more above
its smallest size recorded. Disease recurrence in the complete
responders was documented by biopsy. Serum levels of
mucin-like carcinoma-associated antigen (MCA) were
monitored in all patients by a two-step solid phase enzyme
immunoassay with a monoclonal mouse antibody (MCA
EIA Kit, Hoffman-La Roche & Co. Ltd, Basle, Switzerland).
Pre-treatment serum levels above 11 Uml-' were regarded as
positive. Similarly, CA 15-3 levels were also measured in the
same serum samples by a solid phase two sites immuno-
radiometric assay (ELSA-CA15-3 kit, 1988, CIS
Bioindustries, Gif-sur-Yvette, France) and pre-treatment
serum levels above 20Uml- I were regarded as positive.
Pharmacokinetics ofdoxorubicin
The pharmacokinetics of doxorubicin were determined in 11
patients (three patients at each dose level and two at
50mgm-2) by a high performance liquid chromatography
(HPLC) assay following the first dose, essentially as
described by Israel et al. (1978) and will be discussed more
fully in a subsequent paper.
Statistical methods
Response rates and toxicities were analysed in the 17
patients who had received G-CSF and doxorubicin. The nine
patients who had received the lower doses ofdoxorubicin (75
and 00 mgm-2) were compared with the eight patients who
had received the higher doses (125 and 150mgm-2). Becaue
the numbers were small Fisher's exact test was used.
Functional status scores were analysed by the Wilcoxon
matched-pair signed rank test and anxiety-depression scores
by McNemar's test, comparing the original pre-treatment
scores with those recorded 2 months after completion of
therapy.
Resus
Anti-tumour effects
The results of treatment are shown in Table I. At 75 and
lOOmgm-2, 5/8 patients (62%) with metastic breast cancer
achieved an objective regression, one being complete (12%).
At 125mgm-2 and 150mgm-2 7/7 patients with metastatic
breast cancer responded, four of them (57%) achieving
complete remission. The patient with ovarian carcinoma
present in each of the latter two groups also achieved a
partial response, and so did 2/4 breast cancer patients in the
control group (not treated with G-CSF). There were
comparatively more complete responders in the two higher
doses group (P=0.086), but this was a pilot study and the
numbers were necessarily small. Nevertheless, an overall
response rate of 80% (12/15) in patients with advanced
breast cancer treated with G-CSF and a median time to
progression of 6 months, range 2-9 months (Figure 2), are
encouraging. Two patients, numbers 3 and 6, died from
progressive disease within 6 weeks of therapy. Both had a
very poor pre-treatment performance score (WHO grade 3)
and failed to achieve significant regression of tumour
burden. Similarly, one patient (number 19) in the control
group, not given G-CSF, died after one course of chemo-
therapy from progressive disease. Tumour responses were
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Fgwe 2 Time to progression (in months) for the 14 patients
treated with G-CSF who achieved a partial or complete response
to chemotherapy. Disease recurrence in the complete responders
was documented by biopsy.
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Fngwe 3 a, Median absolute neutrophil counts mm-3 (ANC) of patients receiving 75mgm-2 of doxorubicin with (0) and with-
out (A) G-CSF (four patients each) and lOOmgm-2 with G-CSF (El, five patients). The heavy line denotes the peripheral neutrophil
profile of the control group. Shaded areas represent the total area of neutropenia (ANC <1,000Mm-3) following the first
doxorubicin dose at 75mgm-2. b, Median ANC of patients receiving G-CSF and doxorubicin at 125 mgm-2 (0, six patients)
and 150mgm-2 ([C1, two patients).
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also documented by measuring serum levels of tumour
markers. Three of five patients who achieved a complete
response had significantly raised pre-treatment levels of
MCA, which in each case returned to normal within 2
months. A similar fall was also found in the CA15-3 levels
of these three patients. Following disease progression/relapse
patients were offered further therapy with cyclo-
phosphamide, methotrexate and 5-fluorouracil. Seven
patients are now assessable for response to second line
chemotherapy and three have obtained objective responses
(42%).
Haematological changes
Total and differential white counts were measured three
times per week during the study. The absolute neutrophil
counts (ANC) are shown in Figure 3. The ANC rose to
normal or above normal levels by day 12-14 at all dose
levels of doxorubicin given with G-CSF infusions, whereas
an ANC>2.5 x 109 1O-1 was not reached until day 19-21 after
75mgm-2 of doxorubicin given without G-CSF. G-CSF
infusion was followed by a rapid increase in peripheral
neutrophil counts up to 40 x 1091-1. The nadir was usually
on day 7 post-chemotherapy when G-CSF was given, but it
occurred on days 12-13 when G-CSF was not given. The
nadir and duration of neutropenia were increased for the
two higher dose levels of doxorubicin (Figure 3b) compared
with the two lower ones (Figure 3a). At 125 mgm-2 recovery
from neutropenia following the third cycle of chemotherapy
was slower than following the first two cycles. Platelet
transfusions were required by 4/8 patients at the two higher
dose levels, but no bleeding complications were seen. Blood
transfusions were required by 4/9 patients in the two lower
doses group and by 7/8 in the other, but in no case did the
haemoglobin drop below 8gdl-'. There were no life-
threatening infections, but 7/8 patients receiving 125 and
150mgm-2 required intravenous antibiotics at least once
because of pyrexia and mucositis. Only one pyrexial episode
was associated with positive blood cultures.
Non-haematological toxicities
Overall toxicities are represented in Figure 4 as the
percentage of patients experiencing significant side-effects by
the end of the full treatment period. There was a marked
difference between the group of patients at the lower dose
levels of doxorubicin (Figure 4a) and the rest (Figure 4b).
The former were managed as outpatients with the exception
of overnight admissions for a blood transfusion at the
completion of chemotherapy in four and one admission for
an infective episode in two (Figure 4a). In contrast, 7/8
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patients given the two higher dose levels (125 and
150mgm-2) had to be admitted. All patients developed
mucositis resulting in three patients requiring parenteral
nutrition, and in two cases this toxicity caused a 1 week
delay in the final cycle of chemotherapy. The difference in
the severity of mucositis between the two groups was
statistically significant (P=0.002). New epithelial toxicities
were also found. The most dramatic one was the develop-
ment of erythema of palms and soles by 7/8 patients in the
higher dose group, which in some cases progressed to
superficial blistering and desquamation. Again, the difference
between the two groups was statistically significant
(P<0.005). A milder epithelial reaction also involved the
vulva and perineum of 3/8 patients associated with vaginal
candidiasis in two. Diarrhoea was reported by some patients
but it was always tolerable and easily controlled. All these
epithelial toxicities clared within 2 weeks.
No patient-has developed clinical cardiotoxicity. The mean
resting LVEF for all patients was 44% (range 40-60%)
before therapy, 48% after receiving 225mgm-2, 45% after
receiving 300mgm-2 and 39% at 375mgm-2. Two patients
at the latter cumulative dose dropped their LVEF by 15%,
but none have developed clinical signs of cardiac failure.
Quality oflife
Fourteen patients receiving G-CSF completed quality of life
questionnaires before, immediately after chemotherapy and,
again, after a further 2 months. Eight scored above the
threshold of the psychological subscale before treatment, and
in five of these the scores increased at the end of chemo-
therapy, indicating worsening of depression and/or anxiety.
However, all but one patient recorded scores within the
normal range 2 months after the completion of treatment
(P<0.05). Thirty-five per cent of patients had normal
functional status before therapy. Of the remaining 65%,
functional status improved significantly in 42%, did not
change in 15% and deteriorated in 8% (P<0.05). Twelve of
14 patients reported pain before therapy and 10 of these
patients had improved by 2 months after it. Similarly, 5/7
patients who had complained of breathlessness in the
original questionnaire reported an improvement in the last
one.
Doxorubicin pharnacokinetics
There was a linear increase in the area under the time-drug
concentration curve (AUC) over the full dose range used.
The kinetic parameters obtained suggest that there is no
change in drug distribution with increased dose (Bronchud et
al., 1988).
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Fugwe 4 Toxicities (WHO coded) represented as percentage of patients developing cytotoxic-related side-effects during and after
chemotherapy. See text for explanation. a, Doxorubicin 75 or lOOmgm-2 every 2 weeks: 1, alopecia (WHO 2, 3); 2, nausea/
vomiting (WHO 2); 3, mucositis (V-1O 2); 4, mucositis (WHO 3); 5, mucositis (WHO 4); 6, diarrhoea (WHO 2); 7, i.v. antibiotics
(WHO 2, 3); 8, platelet transfusions (no bleding); 9, red hands/feet (WHO 1); 10, vulvitis (WHO 2); 11, cardiotoxicity (WHO 1).
b, Doxorubicin 125 or 150mgm-2 every 2 weeks: 1, alopecia (WHO 2, 3); 2, nausea/vomiting (WHO 2); 3, mucositis (WHO 2); 4,
mucositis (WHO 3); 5, mucositis (WHO 4); 6, diarrhoea (WHO 2); 7, i.v. antibiotics (WHO 2, 3); 8, platelet transfusions (no
bleeding); 9, red hands/feet (WHO 2); 10, red hands/feet (WHO 3); 11, vulvitis (WHO 2); 12, cardiotoxicity (WHO 1); 13,
cardiotoxicity (WHO 2).
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Discus
Our previous study in patients with small cell lung cancer
was the first to show that neutropemna and infection could be
reduced by G-CSF following intermittent 'conventional' 3-
weekly chemotherapy (Bronchud et al., 1987). The study
reported here shows that infusions of G-CSF allow dose
escalations of chemotherapy and a decrease in the interval
between doses. For example, if we take 300mgm-2 as the
total dose administered, it would take a patient receiving
75mgm-2 every 3 weeks a minimum of 9 weeks to complete
therapy. This total dose can be administered in 4 weeks
(lOOmgm-2 every 2 weeks) or in 2 weeks (lSOmgm-2)
under G-CSF cover. This represents an increase in dose
intensity of 2.2-4,5-fold. No more than 375mgm-2 total
dose could be given at this dose intensity because of dose-
limiting toxicities: severe mucositis and a severe
desquamative skin rash in areas with.high epithelial turnover
rate. In addition, some non-clinical cardiotoxicity was also
seen at this cumulative dose. This distinct difference in
toxicity between the two lower and the two higher doses of
chemotherapy, particularly after the second and third cycles,
made us consider whether the kinetics of doxorubicin were
non-linear. However, examination of the pharmacokinetic
profiles indicated a linear relationship between dose and
AUC for the range of doses employed and intracellular
accumulation of doxorubicin has been suggested as
responsible for the increase in toxicities (Bronchud et al.,
submitted). None of the toxicities encountered were thought
to be related to G-CSF therapy.
An overall response rate of 80% in patients with advanced
breast cancer, with a median time to progression of 6
months, was achieved in this preliminary phase II study.
Response rates were probably higher at the higher doses, but
the numbers were too small to reach statistical significance.
Two months after doxorubicin-G-CSF therapy there was a
pronounced improvement of symptoms compared with
before treatment. These results are comparable, if not better,
to those obtained with high dose chemotherapy and bone
marrow transplantation (Antman & Gale, 1988; Hortobagyi,
1988), which is only available in a few specialised centres
and carries a significant mortality (10-20%) and morbidity.
In addition, bone marrow rescue is difficult to repeat and
may not be appropriate in those with marrow involved with
malignancy or in those without a suitable related donor.
The importance of dose intensity has previously been
reported for a variety of malignancies (Frei & Canellos,
1980; Cortes et al., 1978; Jones et al., 1987; De Vita, 1986;
De Vita et al., 1987). Many years ago Skipper showed that
in experimental tumour models high dose intensity may
make the difference between 50-100% cures and no cures at
all, with equitoxic cytotoxic regimens (Skipper, 1967).
However, most of the clinical data on the impact of dose-
response in breast cancer come from retrospective studies,
and there is a need for more clinical trials to assess the
importance of both dose intensity and total dose in solid
tumours (Henderson et al., 1988). The availability of G-CSF
will now allow direct testing of more intensive chemotherapy
regimens in a variety of human cancers. The use of
combination chemotherapy should further improve the
clinical results of this new approach. It may give
considerable benefits to patients with advanced cancer and
possibly increase cure rates when used as an adjuvant to
surgery.
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